Table 1.
Baseline characteristics.
| Variables | Cohort 1 (n = 45) | Data available (n) | Cohort 2 (n = 30) | Data available (n) |
|---|---|---|---|---|
| Variables recorded at the time of transplantation | ||||
| Female sex, n (%) | 20 (44.4) | 45 | 16 (53.3) | 30 |
| Recipient age (years), median (IQR) | 52.4 (44.1–55.6) | 45 | 54.7 (42.6–62.2) | 30 |
| Deceased donor, n (%) | 42 (93.3) | 45 | 24 (80.0) | 30 |
| Living donor, n (%) | 3 (6.7) | 45 | 6 (20.0) | 30 |
| Prior kidney transplant, n (%) | 14 (31.1) | 45 | 10 (33.3) | 30 |
| Current CDC panel reactivity ≥10%, n (%) | 7 (20.0) | 35 | 4 (19.0) | 21 |
| Preformed anti‐HLA DSA, n (%)* | 17 (63.0) | 27 | 8 (30.8) | 26 |
| Donor age (years), median (IQR) | 46.0 (31.8–59.0) | 44 | 55 (42–59) | 30 |
| HLA mismatch (A, B, DR), median (IQR) | 3 (2–4) | 44 | 3 (3–4) | 30 |
| Cold ischemia time (hours), median (IQR) | 11.9 (9–17) | 43 | 12.9 (9.1–17.1) | 30 |
| Initial immunosuppression | ||||
| Induction with antithymocyte globulin, n (%) | 17 (37.8) | 45 | 9 (30.0) | 30 |
| Induction with IL‐2 receptor antibody induction, n (%) | 15 (33.3) | 45 | 18 (60.0) | 30 |
| Tacrolimus‐based immunosuppression, n (%) | 31 (68.9) | 45 | 26 (86.7) | 30 |
| Cyclosporine A‐based immunosuppression, n (%) | 13 (28.9) | 45 | 4 (13.3) | 30 |
| mTOR inhibitor‐based immunosuppression, n (%) | 1 (2.2) | 45 | 0 (0) | 30 |
| Peri‐transplant immunoadsorption, n (%) | 19 (42.2) | 45 | 8 (26.7) | 30 |
| Variables recorded at the time of index biopsy | ||||
| Age of study patients (years), median (IQR) | 56.4 (50.4–63.4) | 45 | 58.5 (45.0–65.3) | |
| Years after transplantation, median (IQR) | 4.0 (1.3–10.9) | 45 | 2.8 (0.3–5.3) | 30 |
| Renal parameters | ||||
| Serum creatinine (mg/dl), median (IQR) | 1.45 (1.19–1.95) | 45 | 1.50 (1.18–2.59) | 30 |
| Urinary protein/creatinine ratio (mg/g), median (IQR) | 216 (101–411) | 45 | 432 (235–2258) | 29 |
| Maintenance immunosuppression | ||||
| Triple immunosuppression | 36 (80.0) | 45 | 30 (100) | 30 |
| Dual immunosuppression | 9 (20.0) | 45 | 0 (0) | 30 |
| Tacrolimus, n (%) | 28 (62.2) | 45 | 26 (86.7) | 30 |
| Cyclosporine A ression, n (%) | 14 (31.1) | 45 | 3 (10) | 30 |
| mTOR inhibitor, n (%) | 2 (4.4) | 45 | 1 (1) | 30 |
| Belatacept, n (%) | 1 (2.2) | 45 | 0 (0) | 30 |
| MPA, n (%) | 39 (86.7) | 45 | 28 (93.0) | 30 |
| Steroids, n (%) | 41 (91.1) | 45 | 100 (100) | 30 |
DSA, donor‐specific antibody; CDC, complement‐dependent cytotoxicity; IQR, interquartile range; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin.
*For recipients transplanted before 2009, solid‐phase HLA antibody screening on the wait list was not available [34].